Skip to main content
main-content

21-03-2018 | Targeted therapy | Article

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

Dummer R et al. Lancet Oncol 2018; 19(5): 603-615. doi:10.1016/S1470-2045(18)30142-6

Please log in to get access to this content

Related topics